Antisense is the non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA synthesis.
Researchers have found that a class of RNA molecules, previously thought to have no function, may in fact protect sex cells from self-destructing. These findings will be published in the November 17 issue of the journal Cell.
Inhibiting a particular cancer-causing gene can enhance the cell-killing effects of radiation, a team of radiation oncologists and cancer biologists at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia has found.
The results of a Phase I clinical trial of an experimental gene therapy aimed at treating HIV indicate that the therapy is safe and effective and also might sustain viral loads, according to a study published on Monday in the online edition of the Proceedings of the National Academy of Sciences, the AP/Washington Post reports.
Researchers have designed and tested a molecular therapy in animals that they hope will be a major development in the fight to treat amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease.
Using molecular and cell-based models, researchers at Georgetown University Medical Center have refined the picture of how a cancer-promoting protein associated with Ewing's sarcoma functions.
In an article published in the April issue of Nature Reviews Genetics, two experts at the Weill Medical College of Cornell University sum up the achievements, challenges and promise of a burgeoning field: genetic medicine.
A virus of ocean origin that can cause a range of diseases in several animal species has been found in human blood samples. The virus, or antibodies to it, was found most often in the blood of individuals with liver damage, or hepatitis of unknown cause related to blood exposure.
Bioniche Life Sciences has announced that it has been granted a European patent - EP1432450 - covering the composition and use of a novel oligonucleotide family for the treatment of cancer entitled: "Therapeutically Useful Triethyleneglycol Cholesteryl Oligonucleotides"
Saint Louis University research shows a new class of drugs may hold promise in treating brain chemical problems such as Alzheimer's disease, says the principal investigator of research published in an early on-line version of Peptides.
Pharmaceutical companies around the world still come knocking on Renato Baserga, M.D.,'s door. And for good reason.
An international consortium of genome research institutes and investigators, including Jackson Laboratory Staff Scientists Carol J. Bult, Ph.D., and Martin Ringwald, Ph.D., has reported significant new breakthroughs in understanding how the genes in mammals are controlled.
Children who suffer from a rare disease called progeria, which accelerates aging and often kills patients when they are in their teens, may possibly be helped by drugs being developed to treat cancer.
Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc. (GeneSense), has received notice from the European Patent Office of its intention to grant GeneSense's application for a patent of its novel antisense drug, GTI-2501.
Targeted Genetics Corporation announced today issuance of U.S. patent #6,887,463, entitled, "Methods and Compositions for Gene Therapy for the Treatment of Defects in Lipoprotein Metabolism."
A team of scientists led by Dr. Kuniya Abe from the RIKEN BioResource Center in Japan has performed one of the most comprehensive genome-wide experimental analyses of sense-antisense transcripts to date. Their findings are published in the April issue of the journal Genome Research.
VIRxSYS Corporation reports unexpected and unprecedented findings in its ongoing Phase I clinical trial of its VRX496 therapy in patients with HIV.
Phase 1 clinical trial can be initiated for ASM8, a new inhalation drug that is designed to treat asthma through a unique approach by attacking multiple mediators of the inflammatory mechanism rather than the single mediator approach of current therapies.
By exploiting an HIV protein that readily traverses cell membranes, Carnegie Mellon University scientists have developed a new way to introduce a gene-like molecule called a peptide nucleic acid (PNA) directly into live mammalian cells, including human embryonic stem (ES) cells.
Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc., has been allowed a patent by the Canadian Patent Office entitled "Antitumor Antisense Sequences Directed Against R1 and R2 Components of Ribonucleotide Reductase."
Phase II trials of the first second-generation antisense cancer drug to be used in patients are soon to be underway in the wake of a successful Phase I study, which has demonstrated that the new drug blocks its target gene in exactly the way it is designed to do.